Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Treatment with intravenous immunoglobulins and rituximab in renal transplant recipients with chronic humoral rejection: a multicentre, prospective, randomized, placebo-controlled study.

Next Previous
X
Search
Trial Profile

Treatment with intravenous immunoglobulins and rituximab in renal transplant recipients with chronic humoral rejection: a multicentre, prospective, randomized, placebo-controlled study.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 12 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Immune globulin (Primary) ; Rituximab (Primary)
  • Indications Renal transplant rejection
  • Focus Therapeutic Use

    • Most Recent Events

    • 09 Apr 2022 Status changed from recruiting to completed.
    • 27 Sep 2017 Primary endpoint (Renal glomerular filtration rate estimated at one year after the start of treatment.) has not been met, according to the results presented at the 18th Congress of the European Society for Organ Transplantation
    • 27 Sep 2017 Results presented at the 18th Congress of the European Society for Organ Transplantation

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top